Climb Bio, Inc.
CLYM
$2.33
-$0.15-6.05%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 58.30% | -146.92% | 5.39% | 83.79% | -3,134.47% |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -65.32% | 15.78% | -53.92% | -94.92% | 9,985.33% |
Change in Net Operating Assets | -176.60% | 135.11% | 227.25% | -166.36% | 409.38% |
Cash from Operations | 27.77% | -179.55% | 26.92% | -1,032.68% | 63.33% |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | 100.00% | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 111.38% | 19.96% | 25.60% | -1,335.78% | -136.36% |
Cash from Investing | 111.20% | 19.96% | 25.60% | -644.31% | -170.14% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -- | -- | -87.19% | -98.23% | 855,913.33% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -- | -- | -98.19% | -98.23% | 855,913.33% |
Foreign Exchange rate Adjustments | 200.00% | 57.89% | -152.78% | 468.42% | 167.86% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 89.11% | 1.25% | 23.41% | -165.16% | 890.93% |